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Abstract
Background: Convulsive status epilepticus (CSE) is the most common life-threatening childhood neurological
emergency. Despite this, there is a lack of high quality evidence supporting medication use after first line
benzodiazepines, with current treatment protocols based solely on non-experimental evidence and expert opinion.
The current standard of care, phenytoin, is only 60% effective, and associated with considerable adverse effects.
A newer anti-convulsant, levetiracetam, can be given faster, is potentially more efficacious, with a more tolerable
side effect profile. The primary aim of the study presented in this protocol is to determine whether intravenous (IV)
levetiracetam or IV phenytoin is the better second line treatment for the emergency management of CSE in
children.
Methods/Design: 200 children aged between 3 months and 16 years presenting to 13 emergency departments in
Australia and New Zealand with CSE, that has failed to stop with first line benzodiazepines, will be enrolled into this
multicentre open randomised controlled trial. Participants will be randomised to 40 mg/kg IV levetiracetam infusion
over 5 min or 20 mg/kg IV phenytoin infusion over 20 min. The primary outcome for the study is clinical cessation
of seizure activity five minutes following the completion of the infusion of the study medication. Blinded
confirmation of the primary outcome will occur with the primary outcome assessment being video recorded and
assessed by a primary outcome assessment team blinded to treatment allocation. Secondary outcomes include:
Clinical cessation of seizure activity at two hours; Time to clinical seizure cessation; Need for rapid sequence
induction; Intensive care unit (ICU) admission; Serious adverse events; Length of Hospital/ICU stay; Health care costs;
Seizure status/death at one-month post discharge.
Discussion: This paper presents the background, rationale, and design for a randomised controlled trial comparing
levetiracetam to phenytoin in children presenting with CSE in whom benzodiazepines have failed. This study will
provide the first high quality evidence for management of paediatric CSE post first-line benzodiazepines.
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Background
Convulsive status epilepticus (CSE) is the most common
life-threatening childhood neurological emergency [1]. It
has an annual incidence of 17–23 cases per 100,000 chil-
dren per year, with 22% of patients requiring Rapid Se-
quence Induction (RSI) and Intensive Care Unit (ICU)
admission [2]. Mortality following paediatric CSE is re-
ported at 3–5% and neurological sequelae occur in up to
34% of children [3].
Management guidelines for paediatric CSE recom-
mend early and prompt use of anticonvulsant medica-
tion [4, 5]. Recommendations from the Advanced Life
Support Group [4], the Scottish Intercollegiate Guide-
lines Network [5], the Status Epilepsy Working Party in
the United Kingdom [6], and major textbooks [7, 8], are
broadly similar and universally adopt a stepwise ap-
proach to treatment; 1.Two doses of benzodiazepine;
2.Second line anticonvulsant, with all recommending
phenytoin or fosphenytoin; and 3.Final termination of
CSE with RSI intubation with thiopentone and ICU
admission. While there is reasonable evidence to support
the use of benzodiazepines in CSE there is a paucity of
evidence concerning the type and efficacy of second line
anticonvulsant medication used with management
guidelines based only on expert opinion [4, 5, 9].
The aetiology and outcomes of CSE in children is
different to that of adults, thus adult evidence cannot be
expected to be directly applicable to paediatric practice.
A large population based study of CSE reported that less
than a quarter of the children had a previous history of
CSE. Of those with a first presentation of CSE over half
were previously neurologically normal, a third of epi-
sodes were due to prolonged febrile convulsions, 17% of
episodes were due to central nervous system (CNS)
infection or acute metabolic derangement, with the
remainder of episodes idiopathic or associated with a
pre-existing CNS abnormality [2].
The term CSE was traditionally defined as 30 min of a
continuous generalised tonic-clonic convulsion or recur-
rent tonic-clonic convulsions without recovery of con-
sciousness between each convulsion [10]. Recently a
revised operational definition based on the indication to
commence treatment has defined CSE as seizures of a
duration of five minutes or more [11]. This shortening
of seizure duration for CSE definition is due to evidence
that the natural history for typical generalised convulsive
seizures is to resolve spontaneously by 3–5 min, with
those not doing so requiring medication for termination
[11, 12]. This revised definition has been adopted by re-
cent trials on paediatric CSE [13]. Early medication use
and cessation of seizures in CSE is important. There is a
wealth of animal evidence suggesting that longer sei-
zures are harmful and result in irreversible brain damage
and poorer outcomes [1].
A survey of attending Paediatric Emergency Physi-
cians in Australia and New Zealand confirmed that
benzodiazepines are universally recommended for first
line treatment in CSE and that 88% would use pheny-
toin as a second line agent, in keeping with guideline
recommendations. However there was a large vari-
ation in third line agents, reflecting that the majority
of consultants (68%) would try another agent prior to
RSI [14]. A retrospective review of CSE management
at eight large paediatric emergency departments (EDs)
in New Zealand and Australia over five years identi-
fied 542 patients with CSE and found phenytoin re-
sulted in cessation of seizures in only 60% of the 315
patients who received it as a second line anticonvulsant
for CSE [15]. This success rate is comparable with other
reported series [15–17].
In addition to its less than optimal effectiveness,
phenytoin has a number of features that make it less
than ideal to be used in CSE. Phenytoin is a potent
inducer of hepatic enzymes resulting in reduced levels
of a number of other anticonvulsants and non-
anticonvulsant drugs. Its adverse events include hep-
atotoxicity, pancytopenia and Stevens-Johnson-Syndrome.
Phenytoin can cause cardiac arrhythmias, hypotension,
phlebitis, and severe soft tissue injury from extravasation
and purple glove syndrome. Because of its cardiotoxicity it
has to be given slowly (1 mg/kg/min) [16, 18]. Further-
more, phenytoin cannot be mixed with dextrose, a com-
mon component of paediatric intravenous (IV) fluids [16].
In North America fosphenytoin, the prodrug of pheny-
toin, is increasingly used instead of phenytoin [8, 16].
Although fosphenytoin can be administered more rap-
idly, the additional requirement to be metabolised into
the active phenytoin means that it does not offer any
true time advantages over phenytoin. However, fosphe-
nytoin has a number of other advantages such as the
ability to be administered intramuscularly and decreased
infusion related adverse events, although deaths due to
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fosphenytoin infusions have been reported. Furthermore,
there are no data to show that fosphenytoin is more ef-
fective than phenytoin in stopping seizures. Importantly,
for the purposes of this study, fosphenytoin is neither
available nor approved for use in New Zealand and
Australia.
Newer antiepileptic drugs such as levetiracetam, val-
proate and lacosamide have been proposed [9, 16,
17], and have been reported as effective in case re-
ports and small case series in adults and in children
[19–22]. The most promising, Levetiracetam, a broad
spectrum, antiepileptic drug has been approved for
use for over a decade and is widely used internation-
ally for maintenance seizure prophylaxis for both
focal and generalised seizure disorders in both chil-
dren and adults. An IV formulation of levetiracetam
is available for those unable to take oral preparations
and appears to have an excellent safety profile includ-
ing rapid IV use in children [16, 17, 20, 21, 23–26].
In adults, IV infusions of levetiracetam have been well
tolerated [27], including at dosages and rates of infu-
sion greater than recommended [28].
Levetiracetam has the following potential advantages
when compared to phenytoin for use in CSE. Levetirace-
tam is easy to administer and can be given as a five-
minute infusion into a peripheral IV cannula without the
increased risk of serious adverse events (including
hypotension, cardiac arrhythmias, extravasation or
death). Furthermore, levetiracetam is compatible with
both dextrose and normal saline infusion and has limited
drug interactions.
On the basis of efficacy from the limited cohort data
with levetiracetam, and concerns around low pheny-
toin efficacy and serious adverse events, IV levetirace-
tam is being increasingly used as a second line
anticonvulsant in CSE in children. However, good
quality evidence for IV levetiracetam use in CSE is
lacking, and now is an ideal opportunity to compare it
to phenytoin, the current recommended standard of




The primary aim of the study is to determine whether
IV levetiracetam or IV phenytoin is the better second
line treatment for the emergency management of CSE in
children. Specifically, we hypothesise that children
treated with IV levetiracetam for CSE will do better than
children treated with IV phenytoin in terms of time to
clinical cessation of seizure activity, need for RSI for on-
going seizure management, need for ICU admission, ser-
ious adverse events, length of hospital stay, health care
costs, and long-term outcome.
Design
This is a RCT comparing IV levetiracetam with IV
phenytoin in children presenting to EDs with CSE who
are still seizing after two doses of benzodiazepines. The
study will follow the Consolidated Standards of Report-
ing Trials (CONSORT) guidelines.
Participants
200 children aged between 3 months and 16 years pre-
senting with CSE to EDs. The study is ongoing with 147
participants enrolled as of April 2017.
Setting
The study is taking place in 13 EDs in New Zealand and
Australia that are members of the Paediatric Research in
Emergency Departments International Collaborative
(PREDICT), in New Zealand; Kids First Children’s Hos-
pital, Auckland, Waikato Hospital, Hamilton, and Star-
ship Children’s Hospital, Auckland; in Australia; Princess
Margaret Hospital for Children, Perth, WA, Women’s
and Children’s Hospital, Adelaide, SA, Royal Children’s
Hospital, Melbourne, VIC, Monash Medical Centre,
Clayton, VIC, Children’s Hospital at Westmead, Sydney,
NSW, Sydney Children’s Hospital, Sydney, NSW, John
Hunter Hospital, Newcastle, NSW, Gold Coast Univer-
sity Hospital, Southport, QLD, Lady Cilento Children’s
Hospital, Brisbane, QLD, and Townsville Hospital,
Townsville, QLD. The annual paediatric census of the
participating 13 EDs is approximately 500,000. The cen-





Participants will be administered 40 mg/kg IV levetirace-
tam infusion over 5 min (100 mg/ml levetiracetam (Kep-
pra®, UCB Pharma), maximum 3 g, diluted 1:1 with 0.9%
sodium chloride to a minimum volume of 10 ml) or
20 mg/kg IV phenytoin infusion over 20 min (50 mg/ml
phenytoin (DBL™ Phenytoin, Hameln Pharmaceuticals)
maximum 1 g, diluted 1:4 with 0.9% sodium chloride to
a minimum volume of 20 ml). The primary outcome is
assessed 5 min following the end of the study interven-
tion infusion. However, if seizures persist the alternative
medication will be administered; IV phenytoin infusion
if levetiracetam given first (LP regimen), IV levetirace-
tam if phenytoin given first (PL regimen). See Fig. 1 for
study protocol.
Allocation concealment
A computer generated randomisation code using block
randomisation was created by a statistician independent
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to the study for each site and placed in sequentially num-
bered opaque, sealed and signed, envelopes for each site
by central study pharmacists. Randomisation is stratified
by site and age (≤5 years of age and >5 years of age).
Stratification by age is utilised to account for the different
aetiology of CSE within the paediatric age range.
Inclusion criteria
Children aged between 3 months and 16 years of age
who are currently in CSE, following two doses of benzo-
diazepines (given by parents, paramedics, or hospital
staff ), who present to a study ED. CSE is defined as a
child who is unresponsive with continuing abnormality
of movement (increased tone or jerking) of greater than
five minutes duration, or two or more recurrent convul-
sions without recovery of consciousness between convul-
sions, or three or more convulsions within the preceding
hour, and currently experiencing a convulsion. This def-
inition encompasses the International League Against
Epilepsy (ILAE) seizure types of generalised tonic-clonic
convulsions, secondarily generalised tonic-clonic convul-
sions, and complex partial status epilepticus, but not ab-
sence, myoclonic, tonic and simple partial status
epilepticus.
Exclusion criteria
Exclusion criteria include previous randomisation, regu-
lar phenytoin or levetiracetam use, administration of
second line anticonvulsants (phenytoin, levetiracetam,
phenobarbitone or paraldehyde) in the last 24 h, a man-
agement plan stating refractory to phenytoin, known
contraindication or allergy to levetiracetam or pheny-
toin, CSE due to an obvious major head injury or CSE
due to eclampsia in late pregnancy.
Primary outcome
The primary outcome for the study is clinical cessation
of seizure activity five minutes following the completion
of the infusion of the study medication (primary efficacy
outcome). As study medications have different optimal
infusion rates this will be 10 min after starting study in-
fusions in the case of levetiracetam and 25 min after
starting study infusions in the case of phenytoin. Blinded
confirmation of the primary outcome will occur with the
primary outcome assessment being video recorded and
assessed by a primary outcome assessment team blinded
to treatment allocation.
Secondary outcomes
Secondary outcomes include: 1.Clinical cessation of seiz-
ure activity at two hours following the commencement
of the study infusions without the need for further seiz-
ure management after the initial agent (levetiracetam or
phenytoin); 2.Clinical cessation of seizure activity at two
hours following the commencement of the study treat-
ment regimen without the need for RSI or further
Fig. 1 Participant flow for ConSEPT. Management indicated by dashed lines and boxes without fill will only occur if CSE is on-going at that time
point. Min = minutes, LP = Levetiracetam phenytoin, PL = Phenytoin levetiracetam, LEVE = levetiracetam, PHY = Phenytoin
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seizure management (comparison of LP versus PL regi-
mens); 3.Time to clinical seizure cessation from com-
mencement of study treatment regimen; 4.Need for RSI
with thiopentone for on-going seizure management after
administration of study treatment regimen; 5.ICU ad-
mission; 6.Serious adverse events (primary safety out-
come) including death, airway complications, and
cardiovascular instability (cardiac arrest, arrhythmia and
hypotension requiring intervention); 7.Length of Hos-
pital/ICU stay; 8.Health care costs (total costs associated
with CSE admission); 9.Seizure status at one month post
discharge, or two months post randomisation (whichever
is the earliest); 10.Death at one month one post dis-
charge, or two months post randomisation (whichever is
the earliest).
Study process
At all sites patients arriving in clinically diagnosed CSE
are assigned an Australasian Triage Category score of 1,
as per current procedure, and are immediately taken to
the resuscitation area for management. Standard seizure
care is initiated in accordance with each site’s clinical
practice guidelines, including establishment of IV or
intraosseous (IO) access. All clinical practice guidelines,
Advanced Life Support Group guideline [4], and the
Scottish Intercollegiate Guidelines Network guideline
[5], recommend two doses of benzodiazepine prior to
initiation of second line seizure medications. For the
purposes of the study sites can give their usual benzodi-
azepine type (diazepam, lorazepam, or midazolam),
route (rectal, buccal, oral, intranasal, IV, IO, or intra-
muscular) and dose. Doses given by parents and/or para-
medic staff are regarded as an effective benzodiazepine
dose for the purposes of the study. The minimum dose
and route of each benzodiazepine is detailed in Table 1.
Within each study site’s resuscitation area opaque
study boxes for children ≤5 years of age and >5 years of
age are stored. When potential patients are moved to
the resuscitation areas clinical staff complete a study
Clinical Research Form (CRF) addressing inclusion and
exclusion criteria for the study. If all inclusion criteria,
and no exclusion criteria are present, then clinical staff
should open opaque study boxes. Boxes will be opened
at the time the second dose of benzodiazepine is given,
or on arrival if two doses have already been given, in
order to allow nursing staff appropriate time to draw up
the infusions of second line anticonvulsant agents.
Opaque study boxes contain: An opaque, sealed and
signed, envelope containing randomisation allocation
and infusions instructions; A Timer; A video device and
instructions; Seizure charts; Study information sheet and
consent form.
According to the randomisation allocation clinical staff
will draw up and administer a levetiracetam (5-min infu-
sion) or phenytoin infusion (20-min infusion) (see Fig. 1,
time 0 = start of study infusion). While the first study
medication is being administered clinical staff will draw
up the alternative study medication.
Five minutes following the completion of study medi-
cation infusion a formal assessment of seizure activity
will be performed by the most senior treating physician.
This assessment is video recorded to allow blinded con-
firmation of the primary outcome. The participant will
be examined for the following: i)Increased tone; ii)Jerk-
ing movements (including nystagmoid jerking eye move-
ments); iii)Level of consciousness according to the Alert,
Voice, Pain, Unresponsive (AVPU) scale. Continued seiz-
ure activity is defined as presence of either increased
tone or jerking movements. If seizure activity is present
then the alternative study medication is to be infused
(phenytoin if levetiracetam given or levetiracetam if
Table 1 Benzodiazepine dosing prior to enrolment in ConSEPT
Benzodiazepine Route Minimum dose prior to trial enrolment Recommended dose*
Diazepam IV/IO ≥0.1 mg/kg




Total dose ≥5 mg
0.5 mg/kg
Max 10 mg
Midazolam IV/IO ≥0.1 mg/kg












Total dose ≥2 mg
0.5 mg/kg
Max 10 mg
Lorazepam IV/IO ≥0.05 mg/kg
Total dose ≥2 mg
0.1 mg/kg
Max 4 mg
*As per Advanced Paediatric Life Support guidelines (Australia/New Zealand) [4]
IV Intravenous, IO Intraosseous, IM Intramuscular, PR Per Rectum
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phenytoin given). Five minutes following the completion
of the second infusion (if required) a formal assessment
of seizure activity will again be performed by the most
senior treating physician.
If at any stage seizure activity has ceased (as per above
definition) the time is recorded and participants will fin-
ish the infusion they are currently receiving. No further
infusions will be commenced if participants remain seiz-
ure free. If seizure activity recommences and partici-
pants have only received one study infusion they can be
treated with the other medication if this is felt to be ap-
propriate by the treating team.
Clinical or research staff will collect the following data:
Demographics; Date of presentation; Date and time of
onset of seizure; Benzodiazepine type, dose, route and
time given; Highest recorded temperature during resus-
citation, at home or with ambulance service; Adverse
events occurring prior to starting study medications re-
quiring an intervention (airway repositioning, oral or
nasal airway placement, application of positive pressure
or ventilation with bag mask, tracheal intubation, fluid
bolus, chest compressions, cardiac defibrillation); Ad-
verse events occurring anytime in the first two hours
after starting study infusions (in addition to above aller-
gic reaction, IV/IO access tissued, extravasation of IV in-
fusions, purple glove syndrome, any other clinical events
deemed significant).
Trained research nurses will visit participants daily
while they remain in-patients and contact families one
month following discharge collecting the following data:
Past medical history; Epilepsy/seizure history; Medica-
tion history; Background of presenting event; Family his-
tory; Length of stay in hospital/ICU; IV and nasogastric
fluids use; Ventilator support; Medications; Seizures; Ad-
verse events; Seizure classification during admission;
Neurological investigations.
Blinded confirmation of primary outcome
In order to increase the robustness of the primary out-
come assessment seizure continuation or cessation is
video recorded and will be independently assessed by a
blinded primary outcome assessment committee (com-
prising three study physicians, including at least one
study ED physician and one study neurologist). At the
time of primary outcome assessment the treating team
will record the senior treating physician assessing the
following: 1.Assessment of tone in lower limbs (i.e.
flexion of bilateral ankles for clonus, or flexion of bilat-
eral elbows) - approximately 10 s recording verbally con-
firming the presence or absence of increased tone;
2.Assessment of jerking movements by recording the
hands of the patient (in cases of unilateral seizures the
affected side, in cases of predominantly lower limb sei-
zures the lower limbs) – approximately 20 s recording
verbally confirming the presence or absence of jerking
movements; 3.Assessment of jerking movements by re-
cording the eyes of the patient – approximately 10 s re-
cording verbally confirming the presence or absence of
nystagmoid jerking eye movements; 4.Participant study ID.
Prior to the video’s being reviewed by the blinded pri-
mary outcome assessment committee they will be
reviewed by the study management team and edited so
that any part of the video that confirms study medica-
tion is removed (i.e. syringe driver with study medication
labelled accidentally included in video recording).
Adverse events
An independent three member Data Monitoring Com-
mittee (DMC), comprised of two clinicians each with
both emergency medicine and ethics experience, and a
biostatistician, has been established. The DMC will re-
ceive interim reports every 6 months of adverse events:
Episodes of airway repositioning, oral or nasal airway
placement, application of positive pressure or ventilation
with bag mask, fluid boluses, and extravasation of IV/IO
fluids in the first 2 h after starting study medication in-
fusions; Episodes of tracheal intubation in the first 48 h;
All episodes of chest compressions, cardiac defibrillation,
allergic reactions, or purple glove syndrome.
The following are considered Serious Adverse Events
(SAEs): Death; Serious airway complications in the first
24 h, defined as the “unexpected” use of an endotracheal
tube, LMA; and cricothyrotomy. “Unexpected” is defined
as the use of these interventions when it was not part of
a planned RSI following failure of medical management,
nor airway support required by a patient who develops a
compromised airway secondary to seizure activity or first
line CSE medications e.g. benzodiazepines; Cardiovascu-
lar instability (cardiac arrest or arrhythmia requiring
electrical cardioversion); Any other event that is a life-
threatening event. SAEs will be reported to the principal
investigator within 24 h, and will be reported to the
chair of the DMC within 48 h. The DMC will receive an
interim analysis of trial data following the recruitment
and follow-up of the first 100 participants. The study
will be terminated early if: 1.The DMC, with regards to
currently available evidence, following the death or car-
diac arrest of a participant due to a study medication,
thought that the risks for individual participants out-
weighed the benefits of continuing the study; 2.The in-
dependent DMC, with regards to currently available
evidence, following the analysis from the first 100 partic-
ipants, thought that the risks for individual participants
outweighed the benefits of continuing the study.
Consent and ethical considerations
Due to the life threatening nature of CSE, and the need
for urgent timely treatment, it is not possible to gain
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informed consent prior to randomisation and treatment
in this study. Delayed retrospective consent can be
sought in New Zealand if consent prior to the interven-
tion is impracticable and/or undesirable [29] and in
Australia if prospective consent is not practicable, there
is potential benefit to the patient, risk is low, the re-
search has merit and there is no reason to suspect the
parents would not give consent [30]. Ethics approval for
the study and the accompanying consent process has
been granted by the four ethics committees with govern-
ance for the 13 study sites. Thus written informed con-
sent to remain in the study is sought from parents and
guardians at the earliest possible time after emergency
stabilisation of the CSE, i.e. after seizure cessation or
seizure termination by RSI and intubation, by either
trained research or clinical staff. Data for children whose
parents and guardians do not wish for their child to re-
main in the study is destroyed, apart from demographic
data, and will not be available for data analysis.
The use of videos during resuscitation has been stand-
ard of care in some of the PREDICT EDs, where they
have been used for resuscitation research and found to
be acceptable to families [31]. Consent to use the video
recordings is a separate item on the consent form i.e.
families can take part in the study but not have their
child’s video recordings used. If families do not consent
to the video recordings these are deleted immediately at
the time of consent.
Due to the study being undertaken exclusively in
paediatric participants informed consent is not being
sought from participants, but only from their parents
and guardians.
Two members of the DMC, one in each country, are
available to talk with the parent/guardian(s) on request
if the parent/guardian(s) have concerns about the con-
sent process.
Sample size, power and statistical methods
Using pilot data indicating a phenytoin seizure cessation
rate of 60% [15] a total of 91 participants will be re-
quired to be randomised into each arm for the study to
have at least 80% power to detect a total difference in
seizure cessation rates between levetiracetam and pheny-
toin of 20% (alpha = 0.05). The 80% seizure cessation
rate for levetiracetam that this study is powered for is at
the conservative range of seizure cessation rates re-
ported in retrospective series (75–100%) [19, 21, 22]. To
allow for loss to follow-up a total of 100 participants will
be randomised into each arm of the study.
Given that the five-year pilot study showed an average
of eight possible participants per site per year the study
will require three years to complete (8 participants × 13
sites × 3 years = 312). This allows for a third of possible
participants to be lost due to exclusions, failure to enrol,
or refusal of consent.
Analysis will be by intention to treat. Results from un-
adjusted comparisons between groups will be reported,
together with analyses adjusted for possible imbalances
between groups for results with appropriate data distri-
butions. Categorical outcome variables (including the
primary outcome) will be compared with chi-squared
tests (unadjusted) and logistic regression (adjusted).
Continuous outcome variables will be analysed using
survival analysis and Cox regression. Continuous out-
come variables with skewed distributions will be log-
transformed. Continuous variables will be compared
with unpaired t tests (unadjusted) and linear regression
(adjusted). Continuous outcomes variables with skewed
distributions after log-transformation will be compared
with Mann-Whitney tests. Differences for categorical
and unskewed continuous data will be reported as odds
ratios (95% confidence interval (CI)) or difference be-
tween means (95% CI) respectively. Differences between
log-transformed data will be reported as a ratio of geo-
metric means (95% CI). Differences between skewed
continuous data will be reported as difference between
medians (95% CI). Planned subgroup analysis will be
undertaken by focal or generalised onset of CSE, febrile
or afebrile CSE, and type of benzodiazepine used. Sensi-
tivity analyses will be undertaken using a modified
intention-to-treat dataset (excluding those participants
randomised but in whom seizure activity stopped prior
to the start of the first study infusion) and a per-
protocol dataset.
De-identified data will be collected by trained research
nurses, managed using REDCap electronic data capture
tools, including data range checks, securely hosted at
The University of Auckland, Auckland, New Zealand
[32], and analysed using Stata 12 (Statagroup, College
Station, Texas, USA). Starship Children’s Hospital, Auck-
land, New Zealand, is the co-ordinating centre for the
study. Study sites will be audited for data collection and
management by the co-ordinating centre. No independ-
ent audit of data is planned.
A per-protocol analysis of efficacy will be undertaken
as a sensitivity analysis. A further sensitivity analysis will




The primary outcome does not include electroencephal-
ography (EEG) confirmation of seizure termination.
While it is possible that a number of participants may
have the “termination of seizure status” misclassified fol-
lowing the study infusion the primary end-point of the
study is a pragmatic end-point and reflective of the real
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clinical world practice and clinical decision points. EEG
confirmation of seizure activity is not routinely available
in any of the study sites’ EDs, or indeed internationally
in EDs.
In addition, the lack of EEG confirmation of seizure
activity may possibly result in some pseudo seizures or
seizure mimics enrolled in the study. In reality this is
very unlikely and if such conditions were to be enrolled
the presence of randomisation will make the effect min-
imal on the overall study results.
Those assessing the primary end-point are not blinded
to the assigned intervention group and it is possible that
this lack of blinding could introduce bias. As the two
study interventions have different optimal infusion
times, manufacturing presentations (vials and ampoules),
and due to manufacturing technical difficulties related to
phenytoin’s high pH we could not instigate a blinded
study. However, due to the life threatening nature of
CSE it is unlikely that a physician would report that seiz-
ure activity had terminated when in fact it had not. Fur-
thermore, the independent video confirmation of the
primary outcome assessment will also reduce this pos-
sible bias.
Time line
The study commenced recruitment in March 2015, with
the first patient enrolled on the 19th March 2015. Re-
cruitment is expected to finish in 2018. This study is ex-
pected to provide robust evidence for second line
management of CSE in children.
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